Dosing Down to a Science

OnDose is a simple blood test that helps oncologists to optimize infusional 5-FU therapy on an individual basis. OnDose provides the data for pharmacokinetically-guided dose adjustments of infusional 5-FU to help optimize dosing for patients with colorectal cancer.

In a phase 3, multicenter, randomized study (N=208), optimized dosing demonstrated proven benefits for both efficacy and toxicity.¹

• Provided significantly greater objective response rates (33.7% versus 17.3% with body surface area [BSA]-based dosing; P=.004)¹

• Despite having higher mean doses of 5-FU,* patients experienced significantly less toxicity (P=.003)¹
  • Patients experienced a 78% reduction in grades 3/4 diarrhea¹

• Optimized dosing demonstrated a trend toward increased median survival¹
  • 22 months versus 16 months with BSA-based dosing (P=.08)¹

With OnDose, dosing can be as individual as your patients

The OnDose Results Report (click image below to download a sample) is designed to provide you with an accurate and timely measurement of infusional 5-FU exposure in patients with colorectal cancer. The test results are used to help optimize an individualized dose for the next cycle and help guide your patients' doses into a clinically established target area under the curve range (20-24 mg•h/L).

View information recently presented during the 2010 ASCO Gastrointestinal Cancers Symposium



Extensive 5-FU inter-patient pharmacokinetic variability may result in suboptimal 5-FU dosing of metastatic and adjuvant colon cancer patients on FOLFOX regimens

   OnDose Professional Slide Set

Myriad Genetic Laboratories, Inc.
320 Wakara Way, Salt Lake City, UT 84108

1-800-469-7423 | E-mail: ondose@myriad.com
Myriad, the Myriad logo, OnDose, and the OnDose logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.

>> Benefits Of Testing

>> Order a Test

>> Information on Theraguide^® 5FU, a personalized medicine product to predict toxicity to 5FU-based chemotherapy